Journal Article

Treatment of allergic bronchopulmonary aspergillosis: from evidence to practice

Dhooria, Sahajal, Sehgal, Inderpaul S, Muthu, Valliappan, Agarwal, Ritesh

2020

Overview

Allergic bronchopulmonary aspergillosis (ABPA) is a complex pulmonary disorder caused by dysregulated immune responses against . The disorder usually complicates the course of patients with asthma and cystic fibrosis. Patients with ABPA most often present with asthma that is poorly controlled despite inhaled corticosteroids and long-acting β2 agonists. The treatment of ABPA is complicated due to the occurrence of recurrent exacerbations and spontaneous remissions. The drugs used for treating ABPA include systemic glucocorticoids, antifungal agents and biologics, each with its own benefits and drawbacks. In this review, we illustrate the treatment pathway for ABPA in different situations, using a case-based approach. In each case, we present the options for treatment based on the available evidence from recent clinical trials.

• Publisher: Future Medicine Ltd
• Subject: abpm / Allergic bronchopulmonary aspergillosis / Antifungal agents / Aspergillosis / Asthma / azole / Clinical trials / Cor pulmonale / Corticosteroids / Cystic fibrosis / Expected values / Fungal infections / fungus / Glucocorticoids / Immune response / Immunology / Immunomodulators / Immunosuppressive agents / itraconazole / mycosis / Patients / Pulmonary fibrosis / triazole / Vitamin D / voriconazole / Working groups